Kappos, L. Et Al. 2018. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. The Lancet , vol.391, no.10127 , 1263-1273.

Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., ... Vermersch, P.(2018). Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. The Lancet , vol.391, no.10127, 1263-1273.

Kappos, Ludwig Et Al. "Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study," The Lancet , vol.391, no.10127, 1263-1273, 2018

Kappos, Ludwig Et Al. "Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study." The Lancet , vol.391, no.10127, pp.1263-1273, 2018

Kappos, L. Et Al. (2018) . "Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study." The Lancet , vol.391, no.10127, pp.1263-1273.

@article{article, author={Ludwig Kappos Et Al. }, title={Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study}, journal={The Lancet}, year=2018, pages={1263-1273} }